Bioactive Supplement US12605357B2
Summary
The USPTO has granted Patent US12605357B2 to inventor Wellington Silva for a bioactive supplement combining ten active ingredients including lipoic acid, astaxanthin, glutathione, resveratrol, lycopene, epigallocatechin, curcumin, quercetin, coenzyme Q1, and dry açaí extract. The patent application (No. 17912687) was filed on February 4, 2021, and the grant was issued on April 21, 2026. The supplement is described as serving functions of enhancing immunity, preventing diseases, and assisting in therapeutic treatments.
About this source
GovPing monitors USPTO Patent Grants - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 26 changes logged to date.
What changed
The USPTO issued Patent US12605357B2 on April 21, 2026, granting exclusive intellectual property rights to inventor Wellington Silva for a bioactive supplement composition. The patent covers a formulation combining 100 mg lipoic acid, 1 mg astaxanthin, 10 mg glutathione, 5 mg resveratrol, 5 mg lycopene, 50 mg epigallocatechin, 300 mg curcumin, 400 mg quercetin, 10 mg coenzyme Q1, and 100 mg dry açaí extract. The application (No. 17912687) was filed February 4, 2021.
Affected parties in the pharmaceutical and supplement manufacturing sectors should note that this patent confers enforceable exclusive rights to the claimed composition. Competitors developing similar multi-ingredient immune-support formulations may need to evaluate potential patent infringement exposure and consider design-around strategies or licensing arrangements. Patent holders considering enforcement should consult qualified IP counsel regarding the scope of claims granted under this B2 patent.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Bioactive supplement
Grant US12605357B2 Kind: B2 Apr 21, 2026
Inventors
Wellington Silva
Abstract
The present disclosure relates essentially to a supplement, the function of which is to enhance immunity, prevent various diseases and assist in therapeutic treatments of various diseases, said supplement includes: 100 mg of lipoic acid, 1 mg of astaxanthin, 10 mg of glutathione, 5 mg of resveratrol, 5 mg of lycopene, 50 mg of epigallocatechin, 300 mg of curcumin, 400 mg of quercetin, 10 mg of coenzyme Q1 and 100 mg of dry açaí extract; formulated with the intention of combining substances that serve functions of assisting in the treatment of various diseases, such as: lipoic acid, which helps in the prevention of liver damage from intoxication, and can be used as a coadjuvant for the treatment of liver cirrhosis due to alcoholism and a coadjuvant for the treatment of diabetes and cataracts.
CPC Classifications
A61K 31/353 A61K 31/05 A61K 31/07 A61K 31/122 A61K 31/381 A61K 36/889 A61K 38/063
Filing Date
2021-02-04
Application No.
17912687
Claims
1
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.